New Nanotherapies for Brain Tumors
Development of novel nanotherapeutics to overcome therapy resistance using canine brain tumor as a spontaneous model
This research explores tiny new treatments called nanotherapeutics to help patients with aggressive brain tumors overcome resistance to current therapies.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California at Davis NIH-funded |
| Lab location | 1 site (Davis, United States) |
| Project ID | NIH-11124143 on NIH RePORTER |
What this research studies
High-grade brain tumors like glioblastoma are very difficult to treat, and new drug approvals have been rare because these tumors often become resistant to therapy. This project aims to create innovative nanotherapeutics designed to bypass this resistance. Researchers are using companion dogs with naturally occurring brain tumors as a model, which closely mimics human disease, to test these new treatments. The goal is to target a process called autophagy, which helps tumor cells survive and resist drugs, ultimately improving treatment outcomes.
Who could benefit from this research
Good fit: This foundational research is aimed at eventually benefiting patients diagnosed with high-grade gliomas, including glioblastoma, who face therapy resistance.
Not a fit: Patients without high-grade gliomas or those whose tumors do not exhibit therapy resistance may not directly benefit from this specific approach.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for aggressive brain tumors, potentially extending lives and improving quality of life for patients.
How similar studies have performed: Aminoquinoline drugs, which also target autophagy, have shown positive effects in improving outcomes in some clinical trials, suggesting this approach has promise.
Where this research is happening
Davis, United States
- University of California at Davis — Davis, United States (Active)
Researchers
- Principal investigator: Li, Yuanpei — University of California at Davis
- Study coordinator: Li, Yuanpei
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.